[go: up one dir, main page]

WO2009121219A1 - Utilisation d'arséniure dans la préparation de médicaments anti-viraux - Google Patents

Utilisation d'arséniure dans la préparation de médicaments anti-viraux Download PDF

Info

Publication number
WO2009121219A1
WO2009121219A1 PCT/CN2008/001099 CN2008001099W WO2009121219A1 WO 2009121219 A1 WO2009121219 A1 WO 2009121219A1 CN 2008001099 W CN2008001099 W CN 2008001099W WO 2009121219 A1 WO2009121219 A1 WO 2009121219A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hepatitis
arsenic
preparation
arsenide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2008/001099
Other languages
English (en)
Chinese (zh)
Inventor
丁新侃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009121219A1 publication Critical patent/WO2009121219A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the use of arsenide in the preparation of antiviral drugs.
  • Existing inhibitory viruses are aimed at treating viral infections from a single enzyme that inhibits a viral host.
  • the antiviral drug acyclovir which competitively inhibits the viral MA polymerase, blocks the formation of viral DNA.
  • Another example is the anti-HIV drug Zievdo's rule, which uses ziddorfine triphosphate to mimic a pseudo-substrate, 'competitively inhibits RNA reverse transcriptase, and incorporates into the single-stranded DNA that is being synthesized. In the end, the extension of the viral DNA strand is terminated; to achieve the purpose of inhibiting HIV replication.
  • the object of the present invention is to provide an application of an arsenide in the preparation of an antiviral drug, so that human beings can overcome the infection of various viruses in a short period of time, and reduce the mortality of various viral infections in a large area and a large ratio, thereby saving medical expenses. Reduce sequelae and save the lives of patients.
  • arsenide is: arsenic disulfide s 2 S 2 ), arsenic trisulfide (As 2 S 3 ), tetra-arsenic tetrasulfide (As 4 S 4 ), arsenic trioxide (As 2 O 3 ) or trisulfide Arsenic (As 3 S 3 ).
  • the above viruses are: avian influenza virus, atypical pneumonia virus, measles virus, mumps virus, respiratory syncytial virus, adenovirus, rubella virus, poliovirus, coqi virus, echovirus, round Virus, Norwalk virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis C virus, hepatitis G virus, hepatitis TT virus, herpes simplex virus , Epstein-Barr virus, varicella-zoster virus, cytomegalovirus, retrovirus, human immunoglobulin, human T-cell virus, rabies virus, yellow fever virus, rheumatic encephalitis virus, dengue virus, Hantavirus, Xinjiang hemorrhagic fever virus, human papillomavirus, smallpox virus, influenza virus, Marburg virus, Ebola virus, West Malaysia virus
  • the above-mentioned drugs are tinctures, aqueous preparations, emulsions, mixture preparations, syrups, ointments, suppositories, tablets (enteric tablets, sustained release tablets, controlled release tablets, film coated tablets, etc.) honey pills, : .
  • the invention provides the use of a fragment in the preparation of an antiviral drug.
  • arsenic disulfide (As 2 S 2), arsenic trisulfide (As 2 S 3), tetrasulfide four pieces (As 4 S 4), arsenic trioxide (As 2 0 3) or tris Arsenic trisulfide (As 3 S 3 ).
  • Arsenic disulfide (As 2 S 2 ), known as rhubarb in Chinese medicine, is a devastating destructive effect on all proteases because it is a fragmentation compound, which inactivates all proteases.
  • protease is needed as a medium.
  • DNA polymerase DNA linkase
  • primer enzyme primer enzyme
  • helicase helicase
  • RM polymerase RNA polymerase
  • Realgar can inactivate all proteases, including inactivating the viral nucleic acids, ie DNA and RNA, and blocking the replication of the virus in the human body, thereby acting as an antiviral agent.
  • the above ten herbs, cinnabar, realgar, and pearl are respectively watered or pulverized into very fine powder; bezoar, water tablets, antelope horn powder finely ground, berberine, astragalus, hazelnut, ban GmbH and other four herbs are pulverized into fine powder, and The above powders were formulated, sieved, and mixed. Add appropriate amount of refined honey to make 12 honey pellets. Each time 2 times, 1 capsule each time, warm water to send the moon.
  • Symptoms of the patient fever, cough, phlegm, shortness of breath.
  • X-ray examination showed signs of inflammation in both lungs, and the lungs were thickened.
  • the above ten herbs, cinnabar, realgar, and pearl are respectively watered or pulverized into very fine powder; bezoar, borneol, antelope horn powder finely ground, berberine, astragalus, hazelnut, ban GmbH and other four herbs are crushed into fine powder, and the above Powder matching, sieving, and mixing.
  • the two children were the same class of children, and they were admitted to hospital at almost the same time. No antibiotics were used for the fifth day.
  • Symptoms High fever in the morning, fever after 4 pm, body temperature 38. 8-39. 2 °C. It is accompanied by mild abdominal pain. Blood routine tests did not show abnormal white blood cell elevation. Surgical examination may rule out acute appendicitis; Abdominal B-ultrasound did not detect other organs.
  • Medication cinnabar lg, realgar lg, bezoar lg, antelope horn powder lg, pearl 0. 05g, berberine lg, astragalus lg, medlar lg, water tablets 0. 025g, Ban GmbH 1 g.
  • the above ten herbs, cinnabar, realgar, and pearl are respectively watered or pulverized into very fine powder; bezoar, borneol, antelope horn powder finely ground, berberine, astragalus, hazelnut, ban GmbH and other four herbs are crushed into fine powder, and the above Powder matching, sieving, and mixing.
  • lg realgar 2g-2.
  • lg bezoar 2g, antelope horn powder 2g, pearl 0. lg, berberine 2g, astragalus 2g, hazelnut 2g, water tablet 0. 05g, Ban GmbH 2 g.
  • the above ten herbs, cinnabar, realgar, and pearl are respectively watered or pulverized into very fine powder; bezoar, water tablets, antelope horn powder finely ground, berberine, astragalus, hazelnut, ban GmbH and other four herbs are pulverized into fine powder, and The above powders were formulated, sieved, and mixed. Add appropriate amount of refined honey to make 12 honey pellets. 2 times a day, half a grain each time, warm water to send the month I.
  • the clinical manifestations of the patients were bilateral swelling of the parotid gland, pain, accompanied by fever, body temperature 38. 9- 39. 2 °C, and general discomfort. Swelling involves the inferior gland, sublingual gland, and pain in both ears.
  • Medication cinnabar 2g-2. lg, realgar 2g - 2. lg, bezoar 2g, antelope horn powder 2g, pearl 0. lg, berberine 2g, astragalus 2g, hazelnut 2g, borneol 0. 05g, ⁇ 2 g .
  • the above ten herbs, cinnabar, realgar, and pearl are respectively watered or pulverized into very fine powder; Water tablets, antelope horn powder finely ground, berberine, astragalus, medlar, ban GmbH and other four herbs are pulverized into fine powder, and the powder is mixed with the above powder, sieved and mixed. Add appropriate amount of refined honey to make 12 honey pellets. 2 times a day, 1 capsule each time, warm water to send clothes.
  • cinnabar and realgar are mainly composed of one heavy metal and one arsenic. These two drugs are sufficient to give devastating inactivation to the protease required for viral replication, and inactivate various proteases, including viruses. DNA and RNA.
  • Each pill contains cinnabar and realgar powder or very fine powder 160mg-170mg twice a day, which kills the virus and does not cause too much damage to human organs.
  • the antelope horn powder, pearl, borneol and bezoar have certain effects on the synthesis of viral proteins, which have a certain inhibitory effect on the virus, but Far from the complete destruction of viral proteins by cinnabar and realgar, it belongs to the traditional Chinese medicine.
  • berberine, astragalus and medlar have a certain inhibitory effect on bacteria, and they are called medicines in traditional Chinese medicine.
  • Preparation of an injection preparation with arsenic can save the lives of rabies patients.
  • a patient who is bitten by a rabid dog can inject a arsenic injection (only 10 mg) deep in the wound muscle in the absence of rabies vaccine.
  • arsenic poisoning occurs near the wound muscles, it is only local poisoning, but the rabies virus is inactivated, allowing the patient to save his life.
  • the use of preparations of arsenic such as realgar to participate in the treatment of antiviral infections will reduce viral infections and enable infections of viruses such as HIV, flu, non-pulmonary, rabies and polioviruses. Effective treatment reduces mortality on a large scale and greatly reduces the cost of treatment for antiviral infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'utilisation d'arséniure dans la préparation de médicaments anti-viraux permet de résoudre certains problèmes en termes de coût élevé de la thérapie, de séquelles, etc. Le terme arséniure recouvre l'un des composés suivants: As2S2,As2S3,As4S4,As2O3, et As3S3.L'arséniure peut détruire toutes sortes de protéines enzymes par dissolution et inactivation de l'enzyme, l'arséniure empêchant la duplication du virus in vivo et ayant un effet anti-viral.
PCT/CN2008/001099 2008-04-02 2008-06-05 Utilisation d'arséniure dans la préparation de médicaments anti-viraux Ceased WO2009121219A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810089474.2 2008-04-02
CN200810089474 2008-04-02

Publications (1)

Publication Number Publication Date
WO2009121219A1 true WO2009121219A1 (fr) 2009-10-08

Family

ID=40708290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/001099 Ceased WO2009121219A1 (fr) 2008-04-02 2008-06-05 Utilisation d'arséniure dans la préparation de médicaments anti-viraux

Country Status (2)

Country Link
CN (1) CN101433548A (fr)
WO (1) WO2009121219A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846823A (zh) * 2019-02-15 2019-06-07 李玉良 一种治疗带状疱疹的中药喷雾剂及其制备方法
EP3815699A1 (fr) * 2019-10-28 2021-05-05 Technische Universität München Nouveaux moyens et procédés pour la thérapie et le diagnostic d'infections adénovirales
EP4125863A1 (fr) * 2020-04-03 2023-02-08 Medsenic Utilisation d'un composé d'arsenic pour traiter une tempête de cytokine courte ou longue dans diverses maladies auto-immunes/inflammatoires chez l'homme ou l'animal
EP4201412A4 (fr) * 2020-05-18 2024-06-19 Chemas Co., Ltd. Composition pharmaceutique préventive ou thérapeutique pour une infection à coronavirus comprenant de l'hexoxyde de tétra-arsenic

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727523A (zh) * 2011-04-02 2012-10-17 复旦大学 一种具有抗hiv潜伏作用的药物及其用途
CN102441005A (zh) * 2011-11-30 2012-05-09 北京中医药大学东直门医院 一种抗病毒药物及其制备方法和雄黄在制备抗病毒药物中的应用
CN103961370B (zh) * 2014-05-26 2016-02-24 哈尔滨工业大学 物理交联的pva/peo水凝胶载雌黄量子点透皮药贴及其制备方法
CN114514026A (zh) * 2019-09-24 2022-05-17 安德里亚·萨瓦里诺 硫化砷矿物的溶解方法及其作为治疗剂的用途
US20250152599A1 (en) * 2020-03-13 2025-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd Anti-coronavirus effect and application of p14k inhibitor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114575A (zh) * 1994-07-07 1996-01-10 辽宁利利亚医疗保健品公司 防病健身宝
CN1192921A (zh) * 1997-12-26 1998-09-16 穆永森 一种治疗尖锐湿疣的外用药液及其制作方法
CN1256137A (zh) * 1999-04-21 2000-06-14 杨代昌 治疗艾滋病系列药物的制备方法
CN1357348A (zh) * 2000-12-08 2002-07-10 汤道荃 一种治疗带状疱疹的搽剂
CN1442172A (zh) * 2003-04-02 2003-09-17 李淑凤 治疗疱疹病的外用药
CN1493320A (zh) * 2002-10-28 2004-05-05 孙如海 一种兽用抗病毒药物
CN1548129A (zh) * 2003-05-08 2004-11-24 何玉楼 一种治疗非典型肺炎的中成药

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114575A (zh) * 1994-07-07 1996-01-10 辽宁利利亚医疗保健品公司 防病健身宝
CN1192921A (zh) * 1997-12-26 1998-09-16 穆永森 一种治疗尖锐湿疣的外用药液及其制作方法
CN1256137A (zh) * 1999-04-21 2000-06-14 杨代昌 治疗艾滋病系列药物的制备方法
CN1357348A (zh) * 2000-12-08 2002-07-10 汤道荃 一种治疗带状疱疹的搽剂
CN1493320A (zh) * 2002-10-28 2004-05-05 孙如海 一种兽用抗病毒药物
CN1442172A (zh) * 2003-04-02 2003-09-17 李淑凤 治疗疱疹病的外用药
CN1548129A (zh) * 2003-05-08 2004-11-24 何玉楼 一种治疗非典型肺炎的中成药

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846823A (zh) * 2019-02-15 2019-06-07 李玉良 一种治疗带状疱疹的中药喷雾剂及其制备方法
EP3815699A1 (fr) * 2019-10-28 2021-05-05 Technische Universität München Nouveaux moyens et procédés pour la thérapie et le diagnostic d'infections adénovirales
WO2021083964A1 (fr) * 2019-10-28 2021-05-06 Technische Universität München Nouveaux moyens et procédés de thérapie et de diagnostic d'infections par un virus à adn
EP4125863A1 (fr) * 2020-04-03 2023-02-08 Medsenic Utilisation d'un composé d'arsenic pour traiter une tempête de cytokine courte ou longue dans diverses maladies auto-immunes/inflammatoires chez l'homme ou l'animal
EP4201412A4 (fr) * 2020-05-18 2024-06-19 Chemas Co., Ltd. Composition pharmaceutique préventive ou thérapeutique pour une infection à coronavirus comprenant de l'hexoxyde de tétra-arsenic

Also Published As

Publication number Publication date
CN101433548A (zh) 2009-05-20

Similar Documents

Publication Publication Date Title
WO2009121219A1 (fr) Utilisation d'arséniure dans la préparation de médicaments anti-viraux
Zhou et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial
WO2021155751A1 (fr) Composé de médecine chinoise traditionnelle ayant des fonctions de nettoyage des poumons et de détoxication, et application de celui-ci
Chen et al. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID‐19
Singh et al. Rhabdomyolysis in COVID-19: report of four cases
CN112185479B (zh) 一种槐蕾茶抗新型冠状病毒感染的靶点筛选方法
Mukherjee et al. Rhabdomyolysis in a patient with coronavirus disease 2019
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
CN100358549C (zh) 一种治疗腹泻病的中药组合物
JP2012514583A (ja) 治療における塩化アンモニウムの使用方法
STEPHENS et al. Pseudodiphtheria: prominent pharyngeal membrane associated with fatal paraquat ingestion
WO2021198940A1 (fr) Composition destinée à prévenir ou soigner une infection virale chronique ou aiguë et/ou une septicémie chez l'être humain ou chez l'animal
CN113209087A (zh) 一种抑制冠状病毒的药物组合物及其用途
CN111700998A (zh) 复方中成药在治疗新型冠状病毒感染的肺炎covid-19中的应用
WO2009121218A1 (fr) Utilisation de mercurure dans la préparation d'un mdicament anti-viral
RU2237470C1 (ru) Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты)
JP2023517771A (ja) 抗新型コロナウイルス感染症の医薬品、食品、及び使用
RU2138255C1 (ru) Способ лечения заболеваний вирусной этиологии
WO2011143844A1 (fr) Composition de médecine chinoise traditionnelle pour traiter l'infection du sous-type de virus de la grippe a et procédé de préparation de celle-ci
CN108379329A (zh) 一种抗流感病毒的中药组合物及其制备方法
Sankhe et al. A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID-19 patients
Goud et al. Nimesulide-A drug to be banned completely
WO2017015481A1 (fr) Composition pour le traitement du vrs
Malik et al. Acute salicylism due to accidental ingestion of a traditional medicine
Oluwo et al. Oral manifestations of herbal medicine induced Steven Johnson syndrome in 3 Nigerian paediatric patients: case report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08757409

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08757409

Country of ref document: EP

Kind code of ref document: A1